Opinion|Videos|September 18, 2024
Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib
Medical experts compare the efficacy and safety of new therapies, including FTD/TPI plus bevacizumab and fruquintinib, to regorafenib for metastatic colorectal cancer.
Advertisement
Episodes in this series
Video content above is prompted by the following:
How do these new therapy options (FTD/TPI plus bevacizumab, fruquintinib) compare with regorafenib in terms of efficacy and safety?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Tozorakimab Curbs Multiple COPD Inflammatory Pathways, ERS Data Show
2
Fragmented Care, Financial Strain, Gender Gaps Define Life With COPD
3
FDA Approves Camizestrant for ER+, HER2– mBC With ESR1 Mutations
4
Primary Care Capacity Gaps Threaten Respiratory Prevention
5